Evidence map›Paper›PMID 36354576›Full record

ReviewBioengineering (Basel, Switzerland)2022

Noble Metal Nanoparticles for Point-of-Care Testing: Recent Advancements and Social Impacts.

Keven Luciano, Xiaochuan Wang, Yaning Liu, Gabriella Eyler, Zhenpeng Qin, Xiaohu Xia

Open access · goldAbstract readReview
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Keven LucianoDepartment of Chemistry, University of Central Florida, Orlando, FL 32816, USA.
Xiaochuan WangSchool of Social Work, College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA.
Yaning LiuDepartment of Mechanical Engineering, University of Texas at Dallas, Richardson, TX 75080, USA.
Gabriella EylerSchool of Social Work, College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA.
Zhenpeng QinDepartment of Mechanical Engineering, University of Texas at Dallas, Richardson, TX 75080, USA.ORCID 0000-0003-3406-3045
Xiaohu XiaDepartment of Chemistry, University of Central Florida, Orlando, FL 32816, USA.
University of Central Florida · USThe University of Texas at Dallas · US

Funding

Rapid Diagnostic Test for Respiratory Syncytial Virus by Digital NanobubblesR01AI151374 · NIAID · UNIVERSITY OF TEXAS DALLAS · PI QIN, ZHENPENG · 2020 to 2024
$2.5M
NIAID NIH HHS R01 AI151374NIH HHS R01AI151374
6 · The paper itself

Abstract

Point-of-care (POC) tests for the diagnosis of diseases are critical to the improvement of the standard of living, especially for resource-limited areas or countries. In recent years, nanobiosensors based on noble metal nanoparticles (NM NPs) have emerged as a class of effective and versatile POC testing technology. The unique features of NM NPs ensure great performance of associated POC nanobiosensors. In particular, NM NPs offer various signal transduction principles, such as plasmonics, catalysis, photothermal effect, and so on. Significantly, the detectable signal from NM NPs can be tuned and optimized by controlling the physicochemical parameters (e.g., size, shape, and elemental composition) of NPs. In this article, we introduce the inherent merits of NM NPs that make them attractive for POC testing, discuss recent advancement of NM NPs-based POC tests, highlight their social impacts, and provide perspectives on challenges and opportunities in the field. We hope the review and insights provided in this article can inspire new fundamental and applied research in this emerging field.

Indexed as

disease biomarkernanoparticlenoble metalpoint-of-care testsocial impact

Identifiers

PMID36354576
PMCPMC9687823
OpenAlexW4308527453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.